Rein Therapeutics to Present Groundbreaking Research at ATS 2025 Conference
Rein Therapeutics to Present at ATS 2025
Rein Therapeutics, a pioneering biopharma company, is making waves in the medical community with its pioneering research in pulmonary and fibrosis treatments. They recently announced that an abstract has been accepted for presentation at the prestigious American Thoracic Society (ATS) 2025 International Conference, which will be held in San Francisco, California from May 18-21, 2025. This news signifies a milestone in Rein's commitment to addressing unmet medical needs within the realm of orphan pulmonary diseases.
Presentation Details
The details of this anticipated poster presentation are as follows:
- - Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples
- - Poster Number: P1463
- - Session: B75 - Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis
- - Date & Time: Monday, May 19, 2025, at 11:30 AM PT / 2:30 PM ET
This presentation is expected to draw significant attention from health professionals and researchers, focusing on the innovative applications of Caveolin Scaffolding Peptides in lung injury and idiopathic pulmonary fibrosis (IPF).
About Rein Therapeutics
Founded on the foundation of innovation, Rein Therapeutics is at the forefront of advancing groundbreaking solutions for managing orphan pulmonary diseases. Their leading candidate, LTI-03, showcases a dual mechanism of action designed to enhance the survival of alveolar epithelial cells while simultaneously inhibiting harmful fibrotic signaling pathways.
Anticipation is building for the upcoming Phase 2 clinical trial for LTI-03, expected to commence in the first half of 2025. As a testament to their commitment to novel therapies, Rein also has an additional candidate, LTI-01, which has completed Phase 1b and Phase 2a clinical trials focused on treating loculated pleural effusions. Significantly, LTI-01 has been granted Orphan Drug Designation in both the U.S. and E.U., alongside Fast Track Designation in the U.S., which accelerates its path toward approval.
The support from regulatory agencies reflects the urgent need for effective therapeutic options in these challenging medical contexts. As Rein Therapeutics prepares to showcase its advancements at the ATS 2025, the company continues to make strides in fostering hope for patients afflicted by severe pulmonary conditions.
Conclusion
The upcoming ATS 2025 Conference is not merely a platform for presentations but a gathering of minds dedicated to transforming patient care in the realm of pulmonary diseases. Rein Therapeutics, through its innovative research and strategies, is set to inspire and galvanize its peers and the broader medical community. For updates and more information on their initiatives, interested parties can visit their official website at reintx.com and follow them on LinkedIn and X for the latest news.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.